NCT03827876 Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
| NCT ID | NCT03827876 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Psoriasis Treatment Center of Central New Jersey |
| Condition | Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2019-01-16 |
| Primary Completion | 2019-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 30 participants in total. It began in 2019-01-16 with a primary completion date of 2019-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Eligibility Criteria
Inclusion Criteria: * Male or female adult ≥ 18 years of age; * Diagnosis of chronic plaque-type * Patient with 2-10% BSA * Physician Global Assessment of 2 or greater * Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks Exclusion Criteria: * ˂2 or \>10% BSA * PGA \<2 * Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03827876 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03827876 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT03827876 currently recruiting?
Yes, NCT03827876 is actively recruiting participants. Contact the research team at dreamacres1@aol.com for enrollment information.
Where is the NCT03827876 trial being conducted?
This trial is being conducted at East Windsor, United States.
Who is sponsoring the NCT03827876 clinical trial?
NCT03827876 is sponsored by Psoriasis Treatment Center of Central New Jersey. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.